Reata Pharmaceuticals (Reata Pharmaceuticals) COGS-to-Revenue : 0.04 (As of Jun. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Reata Pharmaceuticals COGS-to-Revenue?

Reata Pharmaceuticals's Cost of Goods Sold for the three months ended in Jun. 2023 was $0.85 Mil. Its Revenue for the three months ended in Jun. 2023 was $22.75 Mil.

Reata Pharmaceuticals's COGS to Revenue for the three months ended in Jun. 2023 was 0.04.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Reata Pharmaceuticals's Gross Margin % for the three months ended in Jun. 2023 was 96.28%.

Reata Pharmaceuticals COGS-to-Revenue Historical Data

The historical data trend for Reata Pharmaceuticals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reata Pharmaceuticals COGS-to-Revenue Chart

Reata Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

COGS-to-Revenue

Get a 7-Day Free Trial

4.69

Reata Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	0.04

Reata Pharmaceuticals COGS-to-Revenue Calculation

Reata Pharmaceuticals's COGS to Revenue for the fiscal year that ended in Dec. 2022 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	2.216
	=	0.00

Reata Pharmaceuticals's COGS to Revenue for the quarter that ended in Jun. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.846	/	22.746
	=	0.04

Reata Pharmaceuticals (NAS:RETA) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Reata Pharmaceuticals's Gross Margin % for the three months ended in Jun. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0.846 / 22.746
	=	96.28 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Reata Pharmaceuticals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Reata Pharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Reata Pharmaceuticals (Reata Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reata Pharmaceuticals Inc (NAS:RETA) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

5320 Legacy Drive, Plano, TX, USA, 75024

Website

https://www.reatapharma.com

Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways. The company's product in the pipeline include bardoxolone methyl; Omaveloxolone and others.

Executives

Steven Ryder	director	234 CHURCH STREET, SUITE 1020, NEW HAVEN CT 06510
Antal Rohit Desai	director, 10 percent owner	C/O PROCEPT BIOROBOTICS CORPORATION, 900 ISLAND DRIVE, REDWOOD CITY CA 94065
Rajiv Patni	officer: EVP, Chief R&D Officer	C/O OCERA THERAPEUTICS, INC., 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301
Bhaskar Anand	officer: SVP, Chief Accounting Officer	5320 LEGACY DRIVE, PLANO TX 75024
Manmeet Singh Soni	officer: COO, CFO and President	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Martin Edwards	director	15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Dawn Carter Bir	officer: Chief Commercial Officer	C/O REATA PHARMACEUTICALS, INC., 2801 GATEWAY DRIVE, SUITE 150, IRVING TX 75063
Christy J. Oliger	director	85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Andrea Loewen	officer: SVP, Global Regulatory Affairs	C/O VITAL THERAPIES, INC., 15010 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Shamim Ruff	director	215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Mcclellan William D. Jr.	director	C/O APOLLO ENDOSURGERY, INC., 1120 S., CAPITAL OF TEXAS HWY, BLDG. 1, SUITE 300, AUSTIN TX 78746
Michael D Wortley	officer: See Remarks	5320 LEGACY DRIVE, PLANO TX 75024
Meyer Colin John	officer: See Remarks	C/O REATA PHARMACEUTICALS, INC., 2801 GATEWAY DR. SUITE 150, IRVING TX 75063
Biogen Inc.	other: See footnotes	225 BINNEY STREET, CAMBRIDGE MA 02142
Samina Khan	officer: SVP, Chief Medical Officer	5320 LEGACY DRIVE, PLANO TX 75024